You are here: Industry Insights > tremelimumab

News List

AstraZeneca’s Imfinzi and Tremelimumab with Chemotherapy Demonstrated Overall Survival Benefit in Trial for Non-Small Cell Lung Cancer americanpharmaceuticalreview
May 08, 2021
The POSEIDON trial was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) ...
Imfinzi, tremelimumab combo flunks SCLC trial pharmatimes
March 19, 2020
AstraZeneca has released new high-level data from the final analysis of the Phase III CASPIAN trial, showing that the addition of the anti-CTLA4 antibody tremelimumab ...
Imfinzi Confirmed Sustained Overall Survival Benefit in Small Cell Lung Cancer Trial americanpharmaceuticalreview
March 18, 2020
High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained.
Imfinzi’s success in ES-SCLC not matched in combo with tremelimumab pharmaceutical-technology
March 18, 2020
AstraZeneca’s Imfinzi (durvalumab) plus standard of care (SoC) chemotherapies caused a sustained, clinically meaningful overall survival (OS) benefit in first line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Imfinzi cancer combo falls short in DANUBE trial pharmatimes
March 09, 2020
AstraZeneca has released an update from its Phase III DANUBE trial, assessing Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer.
Imfinzi combination fails advanced lung cancer study europeanpharmaceuticalreview
August 23, 2019
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
AstraZeneca’s tremelimumab fails another phase 3 cancer trial fiercebiotech
December 28, 2018
AstraZeneca’s tremelimumab has come up short in another phase 3 trial. Having failed to improve outcomes in metastatic non-small cell lung cancer (NSCLC).....
AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial pharmaceutical-technology
November 19, 2018
AstraZeneca has announced its Phase III MYSTIC trial of Imfinzi alone and Imfinzi combined with tremelimumab in untreated non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint.
Combination of AstraZeneca's Imfinzi, tremelimumab fails to hit goals of third-line lung cancer study firstwordpharma
April 25, 2018
AstraZeneca said that the phase III ARCTIC study of the combination of Imfinzi (durvalumab) and tremelimumab failed to meet the significant and clinically significant improvement in its primary endpoint